Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

The "most promising areas" are integrated device manufacturers (IDMs) and high-end outsourced assembly and test (OSAT) ...

(Reuters) - Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling subdued demand for its genetic tests and diagnostic tools ...

The city-state will also invest an additional $1 billion in research infrastructure for the semiconductor and biotechnology sectors.

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Illumina (ILMN-1.51%) is the industry leader in using short-read sequencing technology, which breaks DNA into short segments to aid in analysis for genetic research, testing, and medical treatment.